On September 11, 2017, Ocasio, Cory A.; Sansook, Supojjanee; Jones, Rhiannon; Roberts, Justin M.; Scott, Thomas G.; Tsoureas, Nikolaos; Coxhead, Peter; Guille, Matthew; Tizzard, Graham J.; Coles, Simon J.; Hochegger, Helfrid; Bradner, James E.; Spencer, John published an article.SDS of cas: 35444-44-1 The title of the article was Pojamide: An HDAC3-Selective Ferrocene Analogue with Remarkably Enhanced Redox-Triggered Ferrocenium Activity in Cells. And the article contained the following:
A ferrocene containing ortho-aminoanilide, N1-(2-aminophenyl)-N8-ferrocenyloctanediamide, 2b (Pojamide) displayed nanomolar potency vs. HDAC3. Compared to RGFP966, a potent and selective HDAC3 inhibitor, Pojamide displayed superior activity in HCT116 colorectal cancer cell invasion assays; however, TCH106 and Romidepsin, potent HDAC1 inhibitors, outperformed Pojamide in cellular proliferation and colony formation assays. Together, these data suggest that HDAC 1 and 3 inhibition is desirable to achieve maximum anticancer benefits. Addnl., the authors explored Pojamide-induced redox-pharmacol. Indeed, treating HCT116 cells with Pojamide, SNP (Na nitroprusside) and glutathione (GSH) led to greatly enhanced cytotoxicity and DNA damage attributed to activation to an Fe(III) species. The experimental process involved the reaction of Methyl 6-chloro-6-oxohexanoate(cas: 35444-44-1).SDS of cas: 35444-44-1
The Article related to pojamide ferrocene analog preparation cellular ferrocenium activity anticancer agent, ferrocenyloctanediamide ferrocene containing ortho aminoanilide preparation anticancer agent and other aspects.SDS of cas: 35444-44-1
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics